Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 6—June 2022

Economic Burden of Reported Lyme Disease in High-Incidence Areas, United States, 2014–2016

Sarah A. HookComments to Author , Seonghye Jeon, Sara A. Niesobecki, AmberJean P. Hansen, James I. Meek, Jenna K.H. Bjork, Franny M. Dorr, Heather J. Rutz, Katherine A. Feldman, Jennifer L. White, P. Bryon Backenson, Manjunath B. Shankar, Martin I. Meltzer, and Alison F. Hinckley
Author affiliations: Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (S.A. Hook, A.F. Hinckley); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S. Jeon, M.B. Shankar, M.I. Meltzer); Connecticut Emerging Infections Program, Yale School of Public Health, New Haven, Connecticut, USA (S.A. Niesobecki, A.P. Hansen, J.I. Meek); Minnesota Department of Health, St. Paul, Minnesota, USA (J.K.H. Bjork, F.M. Dorr); Maryland Department of Health, Baltimore, Maryland, USA (H.J. Rutz, K.A. Feldman); New York State Department of Health, Albany, New York, USA (J.L. White, P.B. Backenson)

Main Article

Table 6

Impact of disease category, age group, sex, and state on total societal cost of Lyme disease per participant, United States, 2014–2016 (n = 613)*

Variable % Difference Total cost difference, 2016 US dollars (95% CI)
Baseline cost†
305 (206–451)
Lyme disease category
Confirmed, localized Referent Referent
Confirmed, disseminated 120 367 (188–545)
181 (71–291)
Age group, y
<18 Referent Referent
18–45 96 293 (107–479)
46–65 108 331 (175–486)
84 (−28 to 195)
F Referent Referent
35 (−26 to 95)
Connecticut Referent Referent
Maryland 0 0 (−76 to 76)
Minnesota 75 229 (114–345)
New York −6 −19 (−119 to 82)

*Results from sample-weighted multivariable linear regression analysis. The model includes independent variables of interest (i.e., disease category, age group, sex, and state), while controlling for insurance status, income, and study year (Appendix). Adjusted R2 = 0.19. †Baseline cost represents a patient with confirmed localized Lyme disease, female, <18 years of age, residing in Connecticut, without private insurance, with income <$60,000, in the study year of 2014.

Main Article

Page created: April 03, 2022
Page updated: May 22, 2022
Page reviewed: May 22, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.